Seeking Alpha

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form ...

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...
Business Insider

Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in ...

PARIS and TARRYTOWN, N.Y., March 10, 2018 /PRNewswire/ -- Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary ...
WIVB-TV

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form ...

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
Business Insider

Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent ...

TARRYTOWN, N.Y. and BRIDGEWATER, N.J., April 25, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) ...
FiercePharma

Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection ...

TARRYTOWN, N.Y. and BRIDGEWATER, N.J, Dec. 11, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that UnitedHealth Group will provide preferred access to Praluent ...
Finanznachrichten

Regeneron Pharmaceuticals, Inc.: Praluent (alirocumab) Injection Receives FDA Approval to ...

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...